Moderna, Inc.
Combination Continues To Show Durable Melanoma Benefits
After a median follow-up of 60.3 months, the combination continued to show durable benefits, reducing the risk of recurrence or death by 49% compared with KEYTRUDA alone, meeting the study's primary endpoint of recurrence-free survival (RFS).
The combination also improved the key secondary endpoint of distant metastasis-free survival (DMFS), lowering the risk of distant metastasis or death by 59% versus KEYTRUDA alone.
Results Reinforce Earlier ASCO Findings
The findings build on the primary analysis and supportive analysis at an approximately three-year follow-up (34.9 months), presented at the 2024 ASCO Annual Meeting, in which intismeran autogene in combination with KEYTRUDA resulted in a 49% RFS risk reduction and 62% DMFS risk reduction compared to KEYTRUDA alone.
The company on Monday said it is expanding its collaboration with the Coalition for Epidemic Preparedness Innovations (CEPI) to develop a vaccine against the Bundibugyo ebolavirus (BDBV).
Moderna Expands CEPI Partnership For Bundibugyo Ebola Vaccine
Moderna's collaboration with CEPI aims to accelerate the development of a potential vaccine using its mRNA technology, which gained prominence during the COVID-19 pandemic.
The urgency of this initiative is underscored by the current outbreak, which has led to over 900 suspected cases and more than 220 deaths, marking it as the third-largest filovirus outbreak in history.
CEPI Commits Up To $50 Million
Under the agreement, CEPI has committed up to $50 million to support preclinical development and Phase 1 clinical testing of Moderna's investigational BDBV vaccine candidate.
The funding will also support parallel manufacturing activities, enabling doses to be produced while clinical evaluation is underway and positioning the program to rapidly advance into large-scale Phase 2/3 trials should the Phase 1 safety and immunogenicity data support further development.
The vaccine candidate is being developed using Moderna's mRNA platform, the same technology that demonstrated rapid development, scalability, and global deployment capabilities during the COVID-19 pandemic.
MRNA Stock Price Activity: Moderna shares were down 2.78% at $45.88 at the time of publication on Monday, according to Benzinga Pro data.
